Exploring lncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment: Advances and challenges

Peixin Dong, Ying Xiong, Junming Yue, Sharon J.B. Hanley, Noriko Kobayashi, Yukiharu Todo, Hidemichi Watari

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Recent studies have revealed both the promise and challenges of targeting long non-coding RNAs (lncRNAs) to diagnose and treat endometrial cancer (EC). LncRNAs are upregulated or downregulated in ECs compared to normal tissues and their dysregulation has been linked to tumor grade, FIGO stage, the depth of myometrial invasion, lymph node metastasis and patient survival. Tumor suppressive lncRNAs (GAS5, MEG3, FER1L4 and LINC00672) and oncogenic lncRNAs (CCAT2, BANCR, NEAT1, MALAT1, H19 and Linc-RoR) have been identified as upstream modulators or downstream effectors of major signaling pathways influencing EC metastasis, including the PTEN/PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, WNT/β-catenin and p53 signaling pathways. TUG1 and TDRG1 stimulate the VEGF-A pathway. PCGEM1 is implicated in activating the JAK/STAT3 pathway. Here, we present an overview of the expression pattern, prognostic value, biological function of lncRNAs in EC cells and their roles within the tumor microenvironment, focusing on the influence of lncRNAs on established EC-relevant pathways. We also describe the emerging classification of EC subtypes based on their lncRNA signature and discuss the clinical implications of lncRNAs as valuable biomarkers for EC diagnosis and potential targets for EC treatment.

Original languageEnglish (US)
Article number234
JournalCancers
Volume11
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Long Noncoding RNA
Cellular Microenvironment
Tumor Microenvironment
Endometrial Neoplasms
Neoplasm Metastasis
Catenins
Mitogen-Activated Protein Kinase Kinases
Phosphatidylinositol 3-Kinases
Vascular Endothelial Growth Factor A
Neoplasms
Down-Regulation
Biomarkers
Lymph Nodes
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Exploring lncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment : Advances and challenges. / Dong, Peixin; Xiong, Ying; Yue, Junming; Hanley, Sharon J.B.; Kobayashi, Noriko; Todo, Yukiharu; Watari, Hidemichi.

In: Cancers, Vol. 11, No. 2, 234, 01.02.2019.

Research output: Contribution to journalReview article

Dong, Peixin ; Xiong, Ying ; Yue, Junming ; Hanley, Sharon J.B. ; Kobayashi, Noriko ; Todo, Yukiharu ; Watari, Hidemichi. / Exploring lncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment : Advances and challenges. In: Cancers. 2019 ; Vol. 11, No. 2.
@article{553deece91ef406c84a2df480f92fcab,
title = "Exploring lncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment: Advances and challenges",
abstract = "Recent studies have revealed both the promise and challenges of targeting long non-coding RNAs (lncRNAs) to diagnose and treat endometrial cancer (EC). LncRNAs are upregulated or downregulated in ECs compared to normal tissues and their dysregulation has been linked to tumor grade, FIGO stage, the depth of myometrial invasion, lymph node metastasis and patient survival. Tumor suppressive lncRNAs (GAS5, MEG3, FER1L4 and LINC00672) and oncogenic lncRNAs (CCAT2, BANCR, NEAT1, MALAT1, H19 and Linc-RoR) have been identified as upstream modulators or downstream effectors of major signaling pathways influencing EC metastasis, including the PTEN/PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, WNT/β-catenin and p53 signaling pathways. TUG1 and TDRG1 stimulate the VEGF-A pathway. PCGEM1 is implicated in activating the JAK/STAT3 pathway. Here, we present an overview of the expression pattern, prognostic value, biological function of lncRNAs in EC cells and their roles within the tumor microenvironment, focusing on the influence of lncRNAs on established EC-relevant pathways. We also describe the emerging classification of EC subtypes based on their lncRNA signature and discuss the clinical implications of lncRNAs as valuable biomarkers for EC diagnosis and potential targets for EC treatment.",
author = "Peixin Dong and Ying Xiong and Junming Yue and Hanley, {Sharon J.B.} and Noriko Kobayashi and Yukiharu Todo and Hidemichi Watari",
year = "2019",
month = "2",
day = "1",
doi = "10.3390/cancers11020234",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Exploring lncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment

T2 - Advances and challenges

AU - Dong, Peixin

AU - Xiong, Ying

AU - Yue, Junming

AU - Hanley, Sharon J.B.

AU - Kobayashi, Noriko

AU - Todo, Yukiharu

AU - Watari, Hidemichi

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Recent studies have revealed both the promise and challenges of targeting long non-coding RNAs (lncRNAs) to diagnose and treat endometrial cancer (EC). LncRNAs are upregulated or downregulated in ECs compared to normal tissues and their dysregulation has been linked to tumor grade, FIGO stage, the depth of myometrial invasion, lymph node metastasis and patient survival. Tumor suppressive lncRNAs (GAS5, MEG3, FER1L4 and LINC00672) and oncogenic lncRNAs (CCAT2, BANCR, NEAT1, MALAT1, H19 and Linc-RoR) have been identified as upstream modulators or downstream effectors of major signaling pathways influencing EC metastasis, including the PTEN/PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, WNT/β-catenin and p53 signaling pathways. TUG1 and TDRG1 stimulate the VEGF-A pathway. PCGEM1 is implicated in activating the JAK/STAT3 pathway. Here, we present an overview of the expression pattern, prognostic value, biological function of lncRNAs in EC cells and their roles within the tumor microenvironment, focusing on the influence of lncRNAs on established EC-relevant pathways. We also describe the emerging classification of EC subtypes based on their lncRNA signature and discuss the clinical implications of lncRNAs as valuable biomarkers for EC diagnosis and potential targets for EC treatment.

AB - Recent studies have revealed both the promise and challenges of targeting long non-coding RNAs (lncRNAs) to diagnose and treat endometrial cancer (EC). LncRNAs are upregulated or downregulated in ECs compared to normal tissues and their dysregulation has been linked to tumor grade, FIGO stage, the depth of myometrial invasion, lymph node metastasis and patient survival. Tumor suppressive lncRNAs (GAS5, MEG3, FER1L4 and LINC00672) and oncogenic lncRNAs (CCAT2, BANCR, NEAT1, MALAT1, H19 and Linc-RoR) have been identified as upstream modulators or downstream effectors of major signaling pathways influencing EC metastasis, including the PTEN/PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, WNT/β-catenin and p53 signaling pathways. TUG1 and TDRG1 stimulate the VEGF-A pathway. PCGEM1 is implicated in activating the JAK/STAT3 pathway. Here, we present an overview of the expression pattern, prognostic value, biological function of lncRNAs in EC cells and their roles within the tumor microenvironment, focusing on the influence of lncRNAs on established EC-relevant pathways. We also describe the emerging classification of EC subtypes based on their lncRNA signature and discuss the clinical implications of lncRNAs as valuable biomarkers for EC diagnosis and potential targets for EC treatment.

UR - http://www.scopus.com/inward/record.url?scp=85062502936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062502936&partnerID=8YFLogxK

U2 - 10.3390/cancers11020234

DO - 10.3390/cancers11020234

M3 - Review article

AN - SCOPUS:85062502936

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 2

M1 - 234

ER -